据市场监管总局2月9日消息，日前，浙江极氪智能科技有限公司根据《缺陷汽车产品召回管理条例》和 《缺陷汽车产品召回管理条例实施办法》的要求，受浙江吉利汽车有限公司委托向国家市场监督管理总 局备案了召回计划。召回编号S2026M0023V：自2026年3月6日起，召回生产日期从2021年7月8日至 2024年3月18日期间生产的部分极氪001WE版汽车，共计38277辆。本次召回范围内的部分车辆，由于 高压动力电池的部件制造一致性原因，长期使用动力电池内阻会异常升高，可能导致部分动力电池性能 下降，极端情况下可能导致动力电池热失控，存在安全隐患。 （文章来源：第一财经） ...

恒指报收27027.16点，涨1.76%，恒生科技指数报收5417.6点，涨1.34%，泡泡玛特、紫金矿业涨逾5%， 中芯国际、中国平安涨逾4%，中国人寿、华虹半导体、百度集团涨逾3%。（AI生成） 恒指报收27027.16点，涨1.76%，恒生科技指数报收5417.6点，涨1.34%，泡泡玛特、紫金矿业涨逾5%， 中芯国际、中国平安涨逾4%，中国人寿、华虹半导体、百度集团涨逾3%。（AI生成） ...

Core Insights - The collaboration between Innovent Biologics and Eli Lilly is valued at over $8.8 billion, marking a significant milestone in the pharmaceutical industry [1][2] - Innovent will receive an upfront payment of $350 million and has the potential to earn up to approximately $8.5 billion in milestone payments related to research, regulatory, and commercialization achievements [1][2] - This partnership represents a shift from traditional licensing agreements to a more integrated model involving deep collaboration on technology platforms and research systems [1][2] Group 1 - Innovent will lead the research and development from drug discovery to clinical concept validation in China, while Eli Lilly will have exclusive global development and commercialization rights outside Greater China [3][4] - The collaboration aims to combine Innovent's efficient drug discovery capabilities with Eli Lilly's extensive global reach, creating a synergistic innovation ecosystem [3][4] - The specific number of projects involved in this collaboration has not been disclosed, but it is indicated to be fewer than similar recent partnerships [3][4] Group 2 - Previous collaborations between Chinese pharmaceutical companies and multinational firms have involved a larger number of projects, such as the partnership between CSPC and AstraZeneca, which included eight projects [4] - Innovent's CEO noted that the success of such technology platform collaborations depends on the uniqueness and validation of the platform technology, as well as the contributions to intellectual property from both parties [4] - This marks the seventh collaboration between Innovent and Eli Lilly, indicating a strong existing relationship and mutual understanding [4][5] Group 3 - The trend of multinational companies shifting early-stage research work to China reflects their recognition of the research efficiency and capabilities of Chinese pharmaceutical firms [5] - Innovent achieved product revenues of 11.9 billion yuan in 2025, marking its first time surpassing 10 billion yuan, with a target of reaching 20 billion yuan by 2027 [5]

日经ETF工银涨3.48%，日经225ETF涨3.36%，日经ETF涨3.23%，日经225ETF易方达涨3.12%。 (本文来自第一财经) 日经ETF工银涨3.48%，日经225ETF涨3.36%，日经ETF涨3.23%，日经225ETF易方达涨3.12%。 (本文来自第一财经) ...

澜起科技涨超50%，兆易创新涨超11%，上海复旦涨超10%，天域半导体、中芯国际均涨超5%。 (本文来自第一财经) 澜起科技涨超50%，兆易创新涨超11%，上海复旦涨超10%，天域半导体、中芯国际均涨超5%。 (本文来自第一财经) ...

近日，一起假"惠民保"诈骗案开庭审理。一个名为"屹腾惠民保障服务"的项目通过编织"国家医保局授 权"、"政府报备"的虚假背景、承诺"无免赔门槛、可带病投保"的超常待遇，在全国30个省份吸引7万多 投保人，非法经营7100余万元。触目惊心的背后是监管漏洞与消费者信息不对称。经查，涉事公司根本 没有保险业务资质，却能大肆非法经营，监管滞后性与监管盲区暴露无遗。虚构政府背景为何没能露出 马脚？是疏于监管，还是不敢监管？另一方面，信息不对称是关键。多数普通投保人对保险法相关规 定、保险产品设计原理都欠缺专业知识，面对"可带病投保、不限既往症"的诱惑，缺乏考证意识。惠民 保的初衷是通过普惠型商业补充医疗保险，缓解居民医疗费用负担。事关民众的保命钱，监管部门必须 填补监管漏洞，完善风险预警机制，提高违法成本。消费者也要提升风险意识，守护好"钱袋子"。 近日，一起假"惠民保"诈骗案开庭审理。一个名为"屹腾惠民保障服务"的项目通过编织"国家医保局授 权"、"政府报备"的虚假背景、承诺"无免赔门槛、可带病投保"的超常待遇，在全国30个省份吸引7万多 投保人，非法经营7100余万元。触目惊心的背后是监管漏洞与消费者信息不对称。经 ...

今天，日本众议院选举结果落地，日经225指数一度大涨5.1%至56999.60点；摩根大通则将2026年底日 经225指数目标从60000点上调至61000点。在股市狂欢的同时，汇市却进一步走低。瑞穗证券预测，高 市早苗的胜选将推动美元兑日元汇率从155-160区间上移至160-165区间。日本股涨汇跌的背离格局进一 步凸显。这一现象并非偶然，而是政策导向、盈利逻辑与宏观风险博弈的集中体现。与日本相同的是韩 国，同样股涨汇跌。日韩作为外向型经济体，股汇背离有着共性逻辑：美联储高利率与两国宽松货币政 策（日本 0.75% 韩国2.5%）形成持续利差，海外资本大规模套息交易盛行压制本币，而汇率贬值又增 厚了跨国企业汇兑收益，支撑股市走强。还有一个背离则是经济"冷"与股市"热"的核心背离。韩国去年 四季度GDP意外萎缩；日本去年三季度经济也一度意外萎缩，从安倍政府时期开始推行的超常规货币政 策（实际负利率）引发通胀上行，但却未能激活经济动能，且付出财政赤字扩大、深陷流动性陷阱等代 价。因此，相比股市的上涨，如何确保经济增长才是各国头疼的问题。 今天，日本众议院选举结果落地，日经225指数一度大涨5.1%至56999 ...

日经ETF工银涨3.48%，日经225ETF涨3.36%，日经ETF涨3.23%，日经225ETF易方达涨3.12%。 日经ETF工银涨3.48%，日经225ETF涨3.36%，日经ETF涨3.23%，日经225ETF易方达涨3.12%。 ...

标普500指数期货现跌0.02%，纳斯达克100指数期货跌0.05%，道琼斯指数期货涨0.1%。 标普500指数期货现跌0.02%，纳斯达克100指数期货跌0.05%，道琼斯指数期货涨0.1%。 (本文来自第一财经) (本文来自第一财经) ...

Summary of Key Points Core Viewpoint - On February 9, a total of 35 stocks were involved with institutional investors, with 17 stocks showing net buying and 18 stocks showing net selling [1]. Group 1: Institutional Net Buying - The top three stocks with the highest net buying by institutions were: - Jushi Holdings (巨力索具) with a net buying amount of 154 million yuan, despite a price drop of 1.96% [2]. - Hunan Silver (湖南白银) with a net buying amount of 118 million yuan, showing a price increase of 9.97% [2]. - Feiwo Technology (飞沃科技) with a net buying amount of 71.6 million yuan, experiencing a price increase of 20% [2]. Group 2: Institutional Net Selling - The top three stocks with the highest net selling by institutions were: - Tongyuan Petroleum (通源石油) with a net selling amount of 168 million yuan, with a price decrease of 3.80% [3]. - Tuori New Energy (拓日新能) with a net selling amount of 155 million yuan, showing a price increase of 9.94% [3]. - Zhongwen Online (中文在线) with a net selling amount of 95.7 million yuan, experiencing a price increase of 20% [3].